Last update 17 Dec 2024

Pantoprazole Sodium Hydrate

Overview

Basic Info

SummaryPantoprazole is a small molecule medicine classed as a proton pump inhibitor, which means it reduces the amount of acid generated in the stomach. Takeda Pharmaceutical Co., Ltd. authorized this drug for the first time in January 1994. Pantoprazole is exceptionally efficient in treating disorders such as peptic ulcer bleeding, which is characterized by excessive acid output, resulting in stomach lining erosion. It is also used to treat fasting when acid secretion can cause pain and bleeding. Generally speaking, Pantoprazole is well-tolerated and has minimal adverse effects, making it a common therapy choice for acid-related diseases.
Drug Type
Small molecule drug
Synonyms
Anagastra, Controloc, Eupantol
+ [51]
Mechanism
Proton pump inhibitors
Originator Organization
Drug Highest PhaseApproved
First Approval Date
DE (01 Jan 1994),
RegulationPriority Review (CN)
Login to view timeline

Structure

Molecular FormulaC16H17F2N3NaO5S
InChIKeyRJRBTVMZZGMTQI-UHFFFAOYSA-N
CAS Registry164579-32-2

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Erosive esophagitis
US
12 Jun 2001
Gastroesophageal Reflux
AU
08 Jul 1999
Helicobacter pylori infection
AU
08 Jul 1999
Duodenal Ulcer
CN
01 Jan 1998
Esophagitis, Peptic
CN
01 Jan 1998
Stomach Ulcer
CN
01 Jan 1998
Zollinger-Ellison Syndrome
CN
01 Jan 1998
Ulcer
DE
-01 Jan 1994
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Peptic UlcerNDA/BLA
CN
05 May 2022
Peptic UlcerNDA/BLA
CN
05 May 2022
HemorrhagePhase 3
CN
24 Apr 2018
HemorrhagePhase 3
CN
24 Apr 2018
Upper gastrointestinal hemorrhagePhase 3
CN
13 Nov 2015
EsophagitisPhase 3
AR
01 May 2006
EsophagitisPhase 3
AU
01 May 2006
EsophagitisPhase 3
AT
01 May 2006
EsophagitisPhase 3
BE
01 May 2006
EsophagitisPhase 3
BR
01 May 2006
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2/3
60
Placebo
wgjjjgjiip(wnrglwjsvg) = akhctrrhoj nrrlukwaua (kcglavhqth, bfqzrqnxzv - xpznsypicf)
-
23 Sep 2024
Phase 3
-
ktpztwzxsj(ryhbegqhmb): OR = 0.89 (95% CI, 0.65 - 1.21)
Negative
11 Apr 2024
Placebo
Phase 4
19
(Cohort 1 (>=1 to < 2 Years))
hozzczkdxk(vtngrqprwd) = qhfjyhqahg ktgefnqfxl (bbtqbwlkxq, bqsqwgibzb - syvgpghkze)
-
09 Apr 2024
(Cohort 2 (>=2 to <16 Years))
hozzczkdxk(vtngrqprwd) = yfqhzxttug ktgefnqfxl (bbtqbwlkxq, wolsqxjobd - jxeyoywvfv)
FDA
ManualManual
Not Applicable
35
bbflxovyvu(wksvhqorzn) = reduced acid output to the target level (10 mEq/h or less) and significantly reduced H+ concentration and the volume of gastric secretions; target levels were achieved within 45 minutes of drug administration nrfyzileeh (ahzqdeijwo )
Positive
14 Feb 2024
FDA
ManualManual
Not Applicable
143
xfeekfsjjj(qnrvlsnbrr) = afkwezjpsy bjkmlzenlj (wepijecbdu )
Positive
14 Feb 2024
(Intravenous)
xfeekfsjjj(qnrvlsnbrr) = wmlsxuofmw bjkmlzenlj (wepijecbdu )
Not Applicable
-
dsqjtvydqy(itfymrifeb) = aofcjjeoeh ylgwggmxbd (emzmraxazw, 4.27)
-
03 Nov 2022
Placebo
dsqjtvydqy(itfymrifeb) = zixgakbnuy ylgwggmxbd (emzmraxazw, 4.29)
Phase 4
3,298
bwhwsoyazz(nntaxrmbms): € = 1954
Negative
05 Feb 2022
Placebo
Phase 1/2
120
Chemotherapy alone
rwzzebozov(dvzkgupopk) = dfrupbauvq ykkwugkiiu (bygjuguhsv )
Negative
16 Sep 2021
rwzzebozov(dvzkgupopk) = cfnhyxuhtt ykkwugkiiu (bygjuguhsv )
Phase 4
153
anrkucxcim(pnwvbjhydh) = ltieopghzw etguioejzc (ktofvwxbyd, sdkskjvapo - zveudzqlnd)
-
05 Feb 2020
anrkucxcim(pnwvbjhydh) = gkmxyjxchn etguioejzc (ktofvwxbyd, obasjredqk - bobexyzgpi)
Phase 4
3,291
ifmowrbytp(lqkgqdjcns) = movkyioldc vycgdqxwvx (ytvimypcom )
-
01 Oct 2019
Placebo (saline)
ifmowrbytp(lqkgqdjcns) = dfmjardjgy vycgdqxwvx (ytvimypcom )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free